Molecular Profile | Unknown unknown |
Therapy | GDC-0980 |
Indication/Tumor Type | colorectal cancer |
Response Type | not applicable |
Create By | csp |
Update By | cstatz |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | Unknown unknown | colorectal cancer | not applicable | GDC-0980 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the dual PI3K/mTOR inhibitor Apitolisib (GDC-0980) reduced vascularization in cell line xenograft models of colorectal cancer (PMID: 23814482). | 23814482 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(23814482) | Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response. | Full reference... |